Results 311 to 320 of about 58,970 (339)
Some of the next articles are maybe not open access.
Quantitation of Phenobarbital and Phenobarbital Sodium in Pharmaceutical Dosage Forms
Journal of Pharmaceutical Sciences, 1984A reverse-phase high-performance liquid chromatographic method for the quantitation of phenobarbital and phenobarbital sodium in pharmaceutical dosage forms (elixir, injection, and tablets) was developed. The method is precise and accurate with percent relative standard deviations of 0.9 (without an internal standard) and 0.7 (with an internal standard)
openaire +3 more sources
Reaction of Phenobarbital with Diphenhydramine
Journal of Pharmaceutical Sciences, 1982Abstract A compound of low water solubility, consisting of pheno- barbital-diphenhydramine in a 1:1 ratio and mp 109.5-110.5° was isolated from a prescription which had been dispensed as a clear solution and later returned with a white sediment. The information obtained suggested that it was either an easily dissociated complex or a salt.
Laurence M. Sirois, Melvin F.W. Dunker
openaire +3 more sources
Identification of Phenobarbital N-Glucosides as Urinary Metabolites of Phenobarbital in Mice
Journal of Pharmaceutical Sciences, 1991Previously, the N-glucosylation of phenobarbital had been observed only in humans. The results of a species screen (mouse, rat, guinea pig, rabbit, cat, dog, pig, and monkey) found that only mice excreted the N-glucosides of phenobarbital in urine after ip administration of sodium phenobarbital.
William H. Soine +4 more
openaire +3 more sources
2018
Phenobarbital and primidone are first-generation antiepileptic drugs currently associated with restricted ranges of antiepileptic indications, despite their acceptable interaction profiles in polytherapy. Although phenobarbital is still widely prescribed as antiepileptic drug in the developing world, safety issues (including risks of dependence and ...
openaire +1 more source
Phenobarbital and primidone are first-generation antiepileptic drugs currently associated with restricted ranges of antiepileptic indications, despite their acceptable interaction profiles in polytherapy. Although phenobarbital is still widely prescribed as antiepileptic drug in the developing world, safety issues (including risks of dependence and ...
openaire +1 more source
The phenobarbital sensitivity syndrome
The American Journal of Medicine, 1953Abstract 1.1. A syndrome of fever, delirium, exfoliative dermatitis and parenchymatous organ degeneration following administration of therapeutic amounts of phenobarbital is reviewed. 2.2. Three additional cases of phenobarbital idiosyncrasy are presented, two fatal and one with recovery. 3.3.
Thomas E. McGeachy, William E. Bloomer
openaire +3 more sources
Phenobarbital pharmacokinetics in neonates
Clinical Pharmacology & Therapeutics, 1978Phenobarbital pharmacokinetics after intravenous injection were studied in 8 neonates with seizures. Subjects ranged in gestational age from 30 to 40 wk. Plasma concentrations of phenobarbital were measured by enzyme‐multiplied immunoassay (EMIT). The volume of distribution (Vd) of phenobarbital was 0.97 ± .15 L/kg which was independent of the dose ...
William H. Pitlick +2 more
openaire +3 more sources
Suppression of Immunity by Phenobarbital
Nature New Biology, 1971PHENOBARBITAL, one of the more commonly used sedatives, behaves as an immunosuppressant in vivo and in vitro when prescribed in conventional, clinically acceptable doses. This observation closely followed experiments in this laboratory which showed that lymphocytes from all patients receiving general- anaesthesia during surgery developed impaired ...
J I Brody, Seungdoo Park
openaire +2 more sources
Pharmacokinetics of phenobarbital in the horse
American Journal of Veterinary Research, 1987SUMMARY Pharmacokinetics of phenobarbital was examined in 6 mature horses after 12 mg of phenobarbital/kg of body weight was infused over 20 minutes. Biexponential decrease in serum phenobarbital concentrations was observed with a distribution-phase half-life of 0.101 ± 0.086 hour (mean ± sd) and a terminal-phase elimination half-life of 18.3 ± 3.65 ...
S H, Duran +3 more
openaire +2 more sources
Phenobarbital-Associated Macroglossia
American Journal of Therapeutics, 2021Rukma Parthvi +2 more
openaire +2 more sources